

Gary R Cutter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6441995/publications.pdf>

Version: 2024-02-01

590
papers

35,124
citations

3668

92
h-index

6177

164
g-index

610
all docs

610
docs citations

610
times ranked

31025
citing authors

#	ARTICLE	IF	CITATIONS
1	The timed 25-foot walk in a large cohort of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 289-299.	1.4	18
2	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 561-572.	1.4	5
3	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 790-800.	1.4	13
4	Video Telehealth Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Is Associated with Clinical Improvement Similar to Center-based Pulmonary Rehabilitation. <i>Annals of the American Thoracic Society</i> , 2022, 19, 331-333.	1.5	10
5	Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. <i>Journal of Neurology</i> , 2022, 269, 1663-1669.	1.8	4
6	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1091-1100.	1.4	10
7	Mendelian randomization in the multivariate general linear model framework. <i>Genetic Epidemiology</i> , 2022, 46, 17-31.	0.6	1
8	Multiple Sclerosis Diagnostic Criteria. <i>Neurology</i> , 2022, 98, 12-13.	1.5	2
9	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	0.9	16
10	The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience. <i>Journal of Neurology</i> , 2022, 269, 1758-1763.	1.8	5
11	Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials. <i>European Journal of Neurology</i> , 2022, 29, 843-854.	1.7	10
12	Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12286.	1.8	4
13	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. <i>Journal of Parkinson's Disease</i> , 2022, 12, 557-570.	1.5	34
14	Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-13.	1.2	0
15	The emerging postural instability phenotype in idiopathic Parkinson disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 28.	2.5	10
16	The Non-Inferiority Complex: What Do Non-Inferiority Trials Tell Us?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 674-676.	3.0	3
17	Treatment for Mild Chronic Hypertension during Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1781-1792.	13.9	215
18	Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103735.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
20	Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 60, 103702.	0.9	1
21	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. Multiple Sclerosis and Related Disorders, 2022, 61, 103757.	0.9	10
22	Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. European Journal of Neurology, 2022, 29, 1106-1116.	1.7	1
23	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	4.9	44
24	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, , 135245852210881.	1.4	5
25	The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Journal of Neurology, 2022, 269, 5319-5327.	1.8	4
26	Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210975.	0.5	4
27	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211020.	0.5	4
28	One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the <sc>MG</sc> Patient Registry. Muscle and Nerve, 2022, 66, 411-420.	1.0	5
29	COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. Multiple Sclerosis and Related Disorders, 2022, 65, 104028.	0.9	3
30	New applications for independent activities of daily living in measuring disability in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 97-106.	1.4	5
31	Rett syndrome: Novel correlations linking >96% genotype, disease severity, and seizures. Translational Science of Rare Diseases, 2021, 5, 131-141.	1.6	1
32	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e111-e120.	1.5	24
33	The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. Journal of Neurology, 2021, 268, 1598-1607.	1.8	49
34	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage: Clinical, 2021, 32, 102834.	1.4	23
35	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1781-1789.	1.4	4
36	A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110211.	1.5	5

#	ARTICLE	IF	CITATIONS
37	An enrichment strategy for clinical trials in SPMS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1884-1893.	1.4	2
38	A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1864-1874.	1.4	7
39	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
40	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. <i>European Journal of Neurology</i> , 2021, 28, 2115-2120.	1.7	12
41	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	1.4	11
42	CSF plasmablasts differentiate MS from other neurologic disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102719.	0.9	3
43	Repurposing Domperidone in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e2313-e2322.	1.5	13
44	Randomized Trial Testing an Online Responsible Vendor Training in Recreational Marijuana Stores in the United States. <i>Journal of Studies on Alcohol and Drugs</i> , 2021, 82, 204-213.	0.6	0
45	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	20
46	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	2.8	72
47	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	0.8	54
48	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. <i>Rheumatology</i> , 2021, 60, 5002-5011.	0.9	13
49	Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 703-714.	1.5	20
50	Uptake and Attitudes About Immunizations in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 327-334.	0.8	7
51	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. <i>Epilepsy and Behavior</i> , 2021, 117, 107862.	0.9	27
52	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	1.7	33
53	A novel Mendelian randomization method with binary risk factor and outcome. <i>Genetic Epidemiology</i> , 2021, 45, 549-560.	0.6	7
54	521 Prevalence and Impact of Restless Legs in Patients with Myasthenia Gravis. <i>Sleep</i> , 2021, 44, A205-A206.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102856.	0.9	13
56	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1523-1532.	2.9	30
57	UAB-LUCSD O'Brien Center for Acute Kidney Injury Research. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F870-F882.	1.3	4
58	Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitis. <i>BMJ Neurology Open</i> , 2021, 3, e000127.	0.7	6
59	How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity. <i>Neurology: Clinical Practice</i> , 2021, 11, 335-341.	0.8	25
60	Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 699.	4.5	225
61	The Importance and Opportunity for Healthy Aging Through Lifestyle, Behavior Medicine Among Older Adults With Multiple Sclerosis: the Case Based on Physical Activity. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	5
62	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2021, 23, 239-244.	0.4	3
63	Abstract 1747: Oncolytic Vesicular Stomatitis Virus expressing a species relevant interferon-beta is safe and provides a survival benefit when added as neoadjuvant to the standard of care for dogs with naturally occurring bone cancer. , 2021, , .		0
64	Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (<sc>MGC</sc>). <i>Muscle and Nerve</i> , 2021, 64, 270-276.	1.0	16
65	Abstract 671: Development of an exosomal biomarker signature to detect minimal residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning. , 2021, , .		0
66	Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	46
67	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1560-e1570.	1.5	19
68	Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 4135-4145.	1.7	13
69	COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	17
70	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. <i>Neurology</i> , 2021, 97, e1334-e1342.	1.5	12
71	Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A targeted, pilot randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106563.	0.8	12
72	Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2021, 122, 108190.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning. <i>Laboratory Investigation</i> , 2021, 101, 1585-1596.	1.7	5
74	Arteriovenous Fistula Nonmaturation: What's the Immune System Got to Do with It?. <i>Kidney360</i> , 2021, 2, 1743-1751.	0.9	4
75	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 940-948.	2.8	23
76	Physical activity and self-reported sleep quality in adults with multiple sclerosis. <i>Disability and Health Journal</i> , 2021, 14, 101133.	1.6	9
77	Demographic, clinical, and symptomatic correlates of subjective sleep quality in adults with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103204.	0.9	3
78	Cannabis Use for Symptom Management Among People with Multiple Sclerosis (PwMS): A 2020 NARCOMS Survey. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, e23-e24.	0.5	0
79	Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110064.	1.5	11
80	Accuracy and Repeatability of Internet-ordered Spectacle Lenses. <i>Optometry and Vision Science</i> , 2021, 98, 1340-1347.	0.6	3
81	Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: a retrospective analysis from the CombiRx trial. <i>European Journal of Neurology</i> , 2021, 29, 515.	1.7	1
82	If Thymectomy Reduces the Risk of Progression of Ocular to Generalized Myasthenia Gravis, Who Should Receive it?. <i>Neurotherapeutics</i> , 2021, 18, 2419-2420.	2.1	1
83	Outcomes in Clinical Trials. , 2021, , 1-25.		0
84	The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing-Remitting Multiple sclerosis: A CombiRx Secondary Analysis. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110421.	0.7	2
85	Randomized Trial Testing an Online Responsible Vendor Training in Recreational Marijuana Stores in the United States. <i>Journal of Studies on Alcohol and Drugs</i> , 2021, 82, 204-213.	0.6	0
86	NARCOMS and Other Registries in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 276-284.	0.4	12
87	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 245-252.	0.4	1
88	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. <i>Multiple Sclerosis Journal</i> , 2021, , 135245852110636.	1.4	1
89	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 747853.	1.1	0
90	Diet Quality Assessment in Wheelchair Users with Multiple Sclerosis. <i>Nutrients</i> , 2021, 13, 4352.	1.7	5

#	ARTICLE	IF	CITATIONS
91	Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 976-986.	1.4	28
92	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1102-1110.	1.4	5
93	Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1540-1549.	1.4	20
94	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101440.	0.9	8
95	Fertility restoration of maize <i>cms</i> altered by a single amino acid substitution within the <i>Rf4</i> transcription factor. <i>Plant Journal</i> , 2020, 101, 101-111.	2.8	35
96	Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. <i>Annals of Neurology</i> , 2020, 87, 419-433.	2.8	52
97	EFFECT size or statistical significance, where to put your money. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101490.	0.9	6
98	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 147-156.	0.5	9
99	Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 181-191.	0.5	2
100	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.000000000010991.	1.5	6
101	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	4.9	64
102	Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1286-1286.	2.2	0
103	Feasibility of "Sit Less, Move More": An intervention for reducing sedentary behavior Among African Americans with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732093234.	0.5	4
104	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , The, 2020, 19, 970-971.	4.9	85
105	Ageing and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642096901.	1.5	20
106	Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2020, 111, 107299.	0.9	24
107	Design and baseline data of a randomized trial comparing two methods for scaling-up an occupational sun protection intervention. <i>Contemporary Clinical Trials</i> , 2020, 97, 106147.	0.8	2
108	Sales to apparently alcohol-intoxicated customers and online responsible vendor training in recreational cannabis stores in a randomized trial. <i>International Journal of Drug Policy</i> , 2020, 83, 102860.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 383, 1796-1798.	13.9	8
110	Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 691-701.	1.2	3
111	Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. <i>Journal of Clinical Neuromuscular Disease</i> , 2020, 22, 11-21.	0.3	7
112	Gender differences in quality of life among patients with myasthenia gravis in China. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 296.	1.0	25
113	Anticholinergic burden among participants in Alzheimer's clinical trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e044362.	0.4	0
114	Comorbidity burden in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e046180.	0.4	0
115	Effect size "one size doesn't fit all. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102587.	0.9	5
116	A longitudinal study of symptom botheration in Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102585.	0.9	7
117	Feasibility of improving dietary quality using a telehealth lifestyle intervention for adults with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102504.	0.9	7
118	Association of Umbilical Cord Milking vs Delayed Umbilical Cord Clamping With Death or Severe Intraventricular Hemorrhage Among Preterm Infants. <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 212-214.	0.2	0
119	Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. <i>Muscle and Nerve</i> , 2020, 62, 261-266.	1.0	15
120	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 109, 39-46.	1.0	23
121	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
122	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
123	Early Cardiac and Cerebral Hemodynamics with Umbilical Cord Milking Compared with Delayed Cord Clamping in Infants Born Preterm. <i>Journal of Pediatrics</i> , 2020, 223, 51-56.e1.	0.9	12
124	Comorbidity is associated with disease activity in MS. <i>Neurology</i> , 2020, 95, e446-e456.	1.5	33
125	Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. <i>Cell</i> , 2020, 181, 1464-1474.	13.5	147
126	Minimal manifestation status and prednisone withdrawal in the MGTX trial. <i>Neurology</i> , 2020, 95, e755-e766.	1.5	17

#	ARTICLE	IF	CITATIONS
127	Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101957.	0.9	6
128	Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 947-958.	2.2	57
129	Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. <i>PLoS ONE</i> , 2020, 15, e0228064.	1.1	9
130	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 245-249.	1.7	9
131	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	0.6	45
132	Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States. <i>Neurology</i> , 2020, 94, 495-500.	1.5	4
133	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020, 20, 204.	0.8	30
134	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii419-iii419.	0.6	3
135	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	0.6	0
136	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. <i>Multiple Sclerosis Journal</i> , 2019, 25, 837-847.	1.4	23
137	Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores. <i>JAMA Neurology</i> , 2019, 76, 1147.	4.5	118
138	Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. <i>Epilepsy and Behavior</i> , 2019, 98, 201-206.	0.9	34
139	Early complement genes are associated with visual system degeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2722-2736.	3.7	30
140	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. <i>Epilepsia</i> , 2019, 60, 1721-1732.	2.6	37
141	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73
142	Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. <i>Muscle and Nerve</i> , 2019, 60, 700-706.	1.0	17
143	Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. <i>Muscle and Nerve</i> , 2019, 60, 707-715.	1.0	56
144	Protocol for a systematically-developed, phase I/II, single-blind randomized controlled trial of treadmill walking exercise training effects on cognition and brain function in persons with multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2019, 87, 105878.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study. <i>Epilepsia</i> , 2019, 60, 2428-2436.	2.6	45
146	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	6.3	433
147	Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. <i>Neurology</i> , 2019, 93, e1452-e1462.	1.5	104
148	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 86-93.	0.9	18
149	LB 1: Premature Infants Receiving Cord Milking or Delayed Cord Clamping: A Randomized Controlled Non-inferiority Trial. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, S682.	0.7	4
150	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. <i>Lancet Neurology</i> , The, 2019, 18, 259-268.	4.9	139
151	Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2019, 97, 105-110.	0.9	34
152	CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13494.	0.5	7
153	Higher satisfaction and adherence with glatiramer acetate 40â€”mg/mL TIW vs 20â€”mg/mL QD in RRMS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 13-21.	0.9	12
154	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 165-172.	0.9	29
155	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984709.	1.5	10
156	Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple Sclerosis. <i>Contemporary Clinical Trials</i> , 2019, 81, 110-122.	0.8	29
157	Evaluation of a web-based fall prevention program among people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 151-156.	0.9	12
158	Hand stereotypies. <i>Neurology</i> , 2019, 92, e2594-e2603.	1.5	29
159	Evolution of clinical trials in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641982654.	1.5	37
160	Cortical Activation Elicited by Subthalamic Deep Brain Stimulation Predicts Postoperative Motor Side Effects. <i>Neuromodulation</i> , 2019, 22, 456-464.	0.4	18
161	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. <i>Pediatric Neurology</i> , 2019, 96, 58-63.	1.0	21
162	Video Telehealth Pulmonary Rehabilitation Intervention in Chronic Obstructive Pulmonary Disease Reduces 30-Day Readmissions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 511-513.	2.5	52

#	ARTICLE	IF	CITATIONS
163	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.5	765
164	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.5	40
165	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.. <i>American Psychologist</i> , 2019, 74, 356-367.	3.8	9
166	Association of Umbilical Cord Milking vs Delayed Umbilical Cord Clamping With Death or Severe Intraventricular Hemorrhage Among Preterm Infants. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1877.	3.8	182
167	Functional gastrointestinal disorders negatively affect health-related quality of life in MS. <i>Neurology: Clinical Practice</i> , 2019, 9, 381-390.	0.8	7
168	Multiple sclerosis: clinical trial design 2019. <i>Current Opinion in Neurology</i> , 2019, 32, 358-364.	1.8	11
169	Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life. <i>Journal of Clinical Neuromuscular Disease</i> , 2019, 20, 173-181.	0.3	29
170	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2555-2565.	1.7	24
171	Implementation of Occupational Sun Safety at a 2-Year Follow-Up in a Randomized Trial: Comparison of Sun Safe Workplaces Policy Intervention to Attention Control. <i>American Journal of Health Promotion</i> , 2019, 33, 683-697.	0.9	7
172	Use of eHealth and mHealth technology by persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 13-19.	0.9	58
173	Declining Financial Capacity in Mild Cognitive Impairment: A Six-Year Longitudinal Study. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 152-161.	0.3	30
174	The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis. <i>Journal of Applied Gerontology</i> , 2019, 38, 1492-1505.	1.0	3
175	An Intervention for Changing Sedentary Behavior Among African Americans With Multiple Sclerosis: Protocol. <i>JMIR Research Protocols</i> , 2019, 8, e12973.	0.5	5
176	Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. <i>Journal</i>		

#	ARTICLE	IF	CITATIONS
181	Factors associated with excessive sitting time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 71-77.	0.9	9
182	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , 2018, 70, 1653-1660.	1.5	17
183	Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 16-21.	0.9	28
184	Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e437.	3.1	11
185	Clinical Trial Design for Myasthenia Gravis. , 2018, , 335-344.		0
186	A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. <i>Multiple Sclerosis Journal</i> , 2018, 24, 951-962.	1.4	11
187	Learning from the past: reflections on recently completed myasthenia gravis trials. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 5-13.	1.8	11
188	Accuracy of Blood Pressure Measurement Devices in Pregnancy. <i>Hypertension</i> , 2018, 71, 326-335.	1.3	74
189	Neurofibromatosis Clinical Trial Consortium. <i>Journal of Child Neurology</i> , 2018, 33, 82-91.	0.7	6
190	Diet quality is associated with disability and symptom severity in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1-e11.	1.5	149
191	Results of a Randomized Trial on an Intervention Promoting Adoption of Occupational Sun Protection Policies. <i>American Journal of Health Promotion</i> , 2018, 32, 1042-1053.	0.9	11
192	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1469-1484.	1.4	41
193	Sun Safe Workplaces. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, 990-997.	0.9	18
194	Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e184080.	2.8	30
195	Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e023231.	0.8	8
196	Gender differences in prednisone adverse effects. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e507.	3.1	25
197	Pseudobulbar affect. <i>Neurology: Clinical Practice</i> , 2018, 8, 472-481.	0.8	10
198	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. <i>Epilepsy Research</i> , 2018, 148, 1-7.	0.8	25

#	ARTICLE	IF	CITATIONS
199	Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials. Archives of Physical Medicine and Rehabilitation, 2018, 99, 2637-2648.	0.5	15
200	Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879361.	1.5	5
201	DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial. Open Heart, 2018, 5, e000780.	0.9	13
202	Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS. Contemporary Clinical Trials, 2018, 71, 154-161.	0.8	25
203	An introduction to Mendelian randomization with applications in neurology. Multiple Sclerosis and Related Disorders, 2018, 24, 72-78.	0.9	19
204	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. Npj Digital Medicine, 2018, 1, .	5.7	16
205	Divergent effects of AKI to CKD models on inflammation and fibrosis. American Journal of Physiology - Renal Physiology, 2018, 315, F1107-F1118.	1.3	73
206	Clinical trials in multiple sclerosis: milestones. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878549.	1.5	7
207	071â€...Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch^{Â®} prescribing program. Journal of Neurology, Neurosurgery and Psychiatry, 2018. 89. A29.2-A29.	0.9	4
208	Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy and Behavior, 2018, 87, 131-136.	0.9	110
209	Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e468.	3.1	83
210	Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. PLoS ONE, 2018, 13, e0197435.	1.1	7
211	Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.. Journal of Clinical Oncology, 2018, 36, 2056-2056.	0.8	2
212	Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems. Topics in Spinal Cord Injury Rehabilitation, 2018, 24, 97-109.	0.8	23
213	Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 183-190.	0.8	19
214	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders, 2017, 12, 70-78.	0.9	92
215	Natalizumab-associated PML. Neurology, 2017, 88, 1197-1205.	1.5	102
216	Publication outcomes of abstracts from the American Society of Hematology Annual Meeting. American Journal of Hematology, 2017, 92, E81-E83.	2.0	5

#	ARTICLE	IF	CITATIONS
217	Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 87-92.	0.9	23
218	Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. <i>Research in Nursing and Health</i> , 2017, 40, 143-152.	0.8	10
219	Assessment of Caregiver Inventory for Rett Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2017, 47, 1102-1112.	1.7	13
220	Effect of an intervention on observed sun protection by vacationers in a randomized controlled trial at North American resorts. <i>Preventive Medicine</i> , 2017, 99, 29-36.	1.6	15
221	Dysregulation of 14 α -3 β proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 466-477.	1.7	28
222	Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2017, 309, 100-110.	1.1	5
223	Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America. <i>American Journal of Health Education</i> , 2017, 48, 90-99.	0.3	13
224	Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note. <i>Multiple Sclerosis Journal</i> , 2017, 23, 982-987.	1.4	7
225	Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 313-323.	0.6	13
226	Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. <i>Pediatric Nephrology</i> , 2017, 32, 1565-1573.	0.9	24
227	High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 88, 1528-1534.	1.5	25
228	Employment and absenteeism in working-age persons with multiple sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 493-502.	1.0	55
229	The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease. <i>Brain Stimulation</i> , 2017, 10, 651-656.	0.7	23
230	To catch a crook, you might try statistics. <i>Nature Reviews Neurology</i> , 2017, 13, 9-10.	4.9	2
231	Pedestrian safety in patients with Parkinson's disease: A case-control study. <i>Movement Disorders</i> , 2017, 32, 1748-1755.	2.2	6
232	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 95-102.	0.9	15
233	Clinical trial design for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1642-1648.	1.4	9
234	Author response: High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 89, 1429-1430.	1.5	0

#	ARTICLE	IF	CITATIONS
235	Which symptoms contribute the most to patients' perception of health in multiple sclerosis?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772830.	0.5	36
236	Challenging Assumptions About African American Participation in Alzheimer Disease Trials. American Journal of Geriatric Psychiatry, 2017, 25, 1150-1159.	0.6	22
237	Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 2017, 58, 1586-1592.	2.6	267
238	Perspectives on marijuana use and effectiveness. Neurology: Clinical Practice, 2017, 7, 333-343.	0.8	24
239	A Randomized Trial of an Advanced Sun Safety Intervention for Vacationers at 41 North American Resorts. Journal of Health Communication, 2017, 22, 951-963.	1.2	10
240	Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. Osteoporosis International, 2017, 28, 2495-2503.	1.3	5
241	Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment. Clinical Gerontologist, 2017, 40, 14-23.	1.2	21
242	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
243	Comparative utility of disability progression measures in PPMS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e358.	3.1	17
244	Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill Patients. Medical Science Monitor, 2017, 23, 649-658.	0.5	12
245	A Framework of Care in Multiple Sclerosis, Part 2. International Journal of MS Care, 2017, 19, 42-56.	0.4	22
246	Women and Neurological Disability: End-of-Life Care and Mortality in Women with MS. , 2017, , 113-126.		0
247	Association Between Early Childhood Caries and Colonization with Genotypes From Mothers. Pediatric Dentistry (discontinued), 2017, 39, 130-135.	0.4	12
248	Randomized trial of thymectomy in myasthenia gravis. Journal of Thoracic Disease, 2016, 8, E1782-E1783.	0.6	21
249	Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. Journal of Alzheimer's Disease, 2016, 50, 1205-1215.	1.2	8
250	International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	1.0	85
251	Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error?. Multiple Sclerosis Journal, 2016, 22, 983-985.	1.4	2
252	Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. BMC Neurology, 2016, 16, 176.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Sustained High Level of Healthcare Worker Adherence With Hand Hygiene Practice Recommendations Using the Patient-as-Observer Approach in the Ambulatory Setting. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1496-1498.	1.0	1
254	Rationale, design, samples, and baseline sun protection in a randomized trial on a skin cancer prevention intervention in resort environments. <i>Contemporary Clinical Trials</i> , 2016, 46, 67-76.	0.8	19
255	3: Azithromycin-based extended spectrum antibiotic prophylaxis for non-elective cesarean delivery: a pragmatic multicenter placebo-controlled double-blind rct. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, S3.	0.7	2
256	Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. <i>Journal of the Neurological Sciences</i> , 2016, 365, 190-198.	0.3	19
257	Long-term registries. <i>Neurology: Clinical Practice</i> , 2016, 6, 97-99.	0.8	2
258	T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 297, 1-8.	1.1	22
259	Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. <i>New England Journal of Medicine</i> , 2016, 375, 1231-1241.	13.9	192
260	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 511-522.	13.9	695
261	Prevalence odds ratio versus prevalence ratio: choice comes with consequences. <i>Statistics in Medicine</i> , 2016, 35, 5730-5735.	0.8	207
262	Randomized Trial of Thymectomy in Myasthenia Gravis. <i>New England Journal of Medicine</i> , 2016, 375, 2005-2007.	13.9	39
263	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	2.8	331
264	Health insurance affects the use of disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2016, 87, 365-374.	1.5	31
265	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 397-408.	0.8	18
266	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 87, 2575-2584.	1.5	76
267	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	1.4	63
268	Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. <i>Pediatric Neurology</i> , 2016, 54, 29-34.	1.0	93
269	Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center. <i>Journal of Hospital Medicine</i> , 2016, 11, 15-20.	0.7	16
270	Pooling Morphometric Estimates: A Statistical Equivalence Approach. <i>Journal of Neuroimaging</i> , 2016, 26, 109-115.	1.0	15

#	ARTICLE	IF	CITATIONS
271	Corrigendum. Neurodegenerative Disease Management, 2016, 6, 178-178.	1.2	50
272	Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. Journal of the Neurological Sciences, 2016, 362, 121-126.	0.3	2
273	Statistical Considerations for an Adaptive Design for a Serious Rare Disease. Therapeutic Innovation and Regulatory Science, 2016, 50, 375-384.	0.8	3
274	Relapses in multiple sclerosis: Relationship to disability. Multiple Sclerosis and Related Disorders, 2016, 6, 10-20.	0.9	36
275	Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database. International Journal of MS Care, 2016, 18, 154-161.	0.4	5
276	A Framework of Care in Multiple Sclerosis, Part 1. International Journal of MS Care, 2016, 18, 314-323.	0.4	9
277	Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2015, 1, 63-71.	1.8	4
278	Sustained use of an occupational sun safety program in a recreation industry: follow-up to a randomized trial on dissemination strategies. Translational Behavioral Medicine, 2015, 5, 361-371.	1.2	8
279	Factors associated with early childhood caries incidence among high caries-risk children. Community Dentistry and Oral Epidemiology, 2015, 43, 366-374.	0.9	34
280	Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study. Human Brain Mapping, 2015, 36, 3749-3760.	1.9	15
281	The Sustainability of an Occupational Skin Cancer Prevention Program. Journal of Occupational and Environmental Medicine, 2015, 57, 1207-1213.	0.9	7
282	VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. Journal of Rehabilitation Research and Development, 2015, 52, 263-272.	1.6	16
283	Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Multiple Sclerosis and Related Disorders, 2015, 4, 241-249.	0.9	21
284	Capacity of patients with brain metastases to make treatment decisions. Psycho-Oncology, 2015, 24, 1448-1455.	1.0	24
285	The promise of futility trials in neurological diseases. Nature Reviews Neurology, 2015, 11, 300-305.	4.9	16
286	Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2015, 1, 46-52.	1.8	27
287	Impact of multiple sclerosis relapse: The NARCOMS participant perspective. Multiple Sclerosis and Related Disorders, 2015, 4, 234-240.	0.9	45
288	Effect of switching from intramuscular interferon β -1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemporary Clinical Trials, 2015, 41, 69-74.	0.8	8

#	ARTICLE	IF	CITATIONS
289	Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 124-136.	0.9	31
290	Differences in Alzheimer disease clinical trial outcomes based on age of the participants. <i>Neurology</i> , 2015, 84, 1121-1127.	1.5	34
291	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	1.4	273
292	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 305-317.	1.4	381
293	Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey. <i>BMJ Open</i> , 2015, 5, e006714-e006714.	0.8	102
294	Causes of death among persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 484-490.	0.9	31
295	Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov. <i>Clinical Trials</i> , 2015, 12, 575-583.	0.7	18
296	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	1.4	39
297	Multiple sclerosis drugs: how much bang for the buck?. <i>Lancet Neurology</i> , The, 2015, 14, 460-461.	4.9	4
298	Prevalence and incidence of early childhood caries among African-American children in Alabama. <i>Journal of Public Health Dentistry</i> , 2015, 75, 42-48.	0.5	21
299	Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 546-554.	0.9	87
300	Two-group time-to-event continual reassessment method using likelihood estimation. <i>Contemporary Clinical Trials</i> , 2015, 45, 340-345.	0.8	6
301	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
302	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	1.4	131
303	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 294-304.	1.4	79
304	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 342-349.	1.4	100
305	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 318-331.	1.4	131
306	Care Partners and Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 253-260.	0.4	26

#	ARTICLE	IF	CITATIONS
307	Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. Patient Preference and Adherence, 2014, 8, 971.	0.8	15
308	Dissemination of Go Sun Smart in Outdoor Recreation: Effect of Program Exposure on Sun Protection of Guests at High-Altitude Ski Areas. Journal of Health Communication, 2014, 19, 999-1016.	1.2	12
309	Distinct populations of label-retaining cells in the adult kidney are defined temporally and exhibit divergent regional distributions. American Journal of Physiology - Renal Physiology, 2014, 307, F1274-F1282.	1.3	9
310	Pubertal Development in Rett Syndrome Deviates From Typical Females. Pediatric Neurology, 2014, 51, 769-775.	1.0	32
311	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 2014, 3, 705-711.	0.9	30
312	Noninvasive Inhaled Nitric Oxide Does Not Prevent Bronchopulmonary Dysplasia in Premature Newborns. Journal of Pediatrics, 2014, 165, 1104-1108.e1.	0.9	35
313	Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle and Nerve, 2014, 49, 483-486.	1.0	73
314	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. Advances in Therapy, 2014, 31, 1134-1154.	1.3	83
315	Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items. BMC Neurology, 2014, 14, 192.	0.8	15
316	Recruitment of participants to a multiple sclerosis trial: The CombiRx experience. Clinical Trials, 2014, 11, 159-166.	0.7	6
317	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. Journal of Neuro-Oncology, 2014, 120, 179-185.	1.4	51
318	Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?. JAMA Neurology, 2014, 71, 945.	4.5	3
319	Effect of Nicotine Replacement Therapy on Quitting by Young Adults in a Trial Comparing Cessation Services. Journal of Public Health Management and Practice, 2014, 20, E7-E15.	0.7	8
320	Low Invasiveness of Pneumococcal Serotype 11A Is Linked to Ficolin-2 Recognition of O-acetylated Capsule Epitopes and Lectin Complement Pathway Activation. Journal of Infectious Diseases, 2014, 210, 1155-1165.	1.9	45
321	Effects of Early Inhaled Nitric Oxide Therapy and Vitamin A Supplementation on the Risk for Bronchopulmonary Dysplasia in Premature Newborns with Respiratory Failure. Journal of Pediatrics, 2014, 164, 744-748.	0.9	41
322	EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet, The, 2014, 383, 1637-1647.	6.3	171
323	Composite end points to assess delay of disability progression by MS treatments. Multiple Sclerosis Journal, 2014, 20, 1494-1501.	1.4	25
324	Clinical trials in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 445-453.	1.0	8

#	ARTICLE	IF	CITATIONS
325	Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?. Multiple Sclerosis Journal, 2014, 20, 1304-1305.	1.4	53
326	Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 349-359.	0.4	34
327	Bifactor structure of clinical disability in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 176-185.	0.9	3
328	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
329	Intensive Care Unit Readmission during Childhood after Preterm Birth with Respiratory Failure. Journal of Pediatrics, 2014, 164, 749-755.e3.	0.9	25
330	Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab. Multiple Sclerosis and Related Disorders, 2014, 3, 505-512.	0.9	6
331	Mutans streptococci enumeration and genotype selection using different bacitracin-containing media. Journal of Microbiological Methods, 2014, 103, 53-57.	0.7	8
332	Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. American Journal of Medicine, 2014, 127, 132-139.	0.6	19
333	The Problem of Spurious Correlations Between Pairs of Brain Metabolite Values Measured in the Same Voxel With Magnetic Resonance Spectroscopy—Reply. JAMA Psychiatry, 2014, 71, 339.	6.0	2
334	Chronobiology of Hypertension in Sickle Cell Disease. Blood, 2014, 124, 4094-4094.	0.6	1
335	Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE, 2014, 9, e105207.	1.1	34
336	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. Interactive Journal of Medical Research, 2014, 3, e3.	0.6	37
337	Treatment trials in progressive MS—current challenges and future directions. Nature Reviews Neurology, 2013, 9, 496-503.	4.9	40
338	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology, 2013, 73, 327-340.	2.8	182
339	A retrospective review of lithium usage in veterans with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 327-333.	0.9	5
340	A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle and Nerve, 2013, 48, 76-84.	1.0	187
341	The magnetic resonance imaging "rule of five": predicting the occurrence of relapse. Multiple Sclerosis Journal, 2013, 19, 1760-1764.	1.4	10
342	MRI lesions: a surrogate for relapses in multiple sclerosis?. Lancet Neurology, The, 2013, 12, 628-630.	4.9	6

#	ARTICLE	IF	CITATIONS
343	Mortality in patients with multiple sclerosis. <i>Neurology</i> , 2013, 81, 184-192.	1.5	199
344	A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. <i>Multiple Sclerosis Journal</i> , 2013, 19, 59-68.	1.4	21
345	Reply. <i>Muscle and Nerve</i> , 2013, 47, 145-146.	1.0	1
346	Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. <i>NeuroImage: Clinical</i> , 2013, 2, 120-131.	1.4	72
347	Constraint-Induced Movement Therapy for the Lower Extremities in Multiple Sclerosis: Case Series With 4-Year Follow-Up. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 753-760.	0.5	38
348	Characteristics of <i>Streptococcus mutans</i> genotypes and dental caries in children. <i>European Journal of Oral Sciences</i> , 2013, 121, 148-155.	0.7	39
349	Substantial burden of dizziness in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 21-28.	0.9	31
350	Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 334-337.	1.1	25
351	EDSS variability before randomization may limit treatment discovery in primary progressive MS. <i>Multiple Sclerosis Journal</i> , 2013, 19, 775-781.	1.4	19
352	The Multiple Sclerosis Intimacy and Sexuality Questionnaire – re-validation and development of a 15-item version with a large US sample. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1197-1203.	1.4	71
353	Seeing in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. <i>Multiple Sclerosis Journal</i> , 2013, 19, 953-960.	1.4	27
354	Disability in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1018-1024.	1.5	150
355	National Variation of Technical Factors in Computed Tomography of the Head. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 486-492.	0.5	5
356	Natural History of Multiple Sclerosis Symptoms. <i>International Journal of MS Care</i> , 2013, 15, 146-156.	0.4	328
357	Genomic Copy Number Variants: Evidence for Association with Antibody Response to Anthrax Vaccine Adsorbed. <i>PLoS ONE</i> , 2013, 8, e64813.	1.1	8
358	Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought. <i>Journal of Medical Internet Research</i> , 2013, 15, e67.	2.1	121
359	Personalized medicine. <i>Neurology: Clinical Practice</i> , 2012, 2, 343-351.	0.8	21
360	Enhancing Industry-Based Dissemination of an Occupational Sun Protection Program with Theory-Based Strategies Employing Personal Contact. <i>American Journal of Health Promotion</i> , 2012, 26, 356-365.	0.9	21

#	ARTICLE	IF	CITATIONS
361	Statistical cures and other fallacies. <i>Multiple Sclerosis Journal</i> , 2012, 18, 387-390.	1.4	7
362	Sustainability of the Dissemination of an Occupational Sun Protection Program in a Randomized Trial. <i>Health Education and Behavior</i> , 2012, 39, 498-502.	1.3	12
363	Response to the Letter "Efficiency loss due to varying cluster sizes in cluster randomized trials and how to compensate for it: comment on You et al. (2011)" by van Breukelen and Candel. <i>Clinical Trials</i> , 2012, 9, 126-127.	0.7	1
364	Cause of death in MS: long-term follow-up of a randomised cohort, 21...years after the start of the pivotal IFN β -1b study. <i>BMJ Open</i> , 2012, 2, e001972.	0.8	37
365	Biomarker Positive and Negative Subjects in the ADNI Cohort: Clinical Characterization. <i>Current Alzheimer Research</i> , 2012, 9, 1135-1141.	0.7	10
366	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012, 33, 1211-1216.	0.8	23
367	Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 63-68.	1.1	59
368	Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 63-70.	0.6	46
369	Treatment With Interferon Beta for Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1627.	3.8	10
370	Biomarker development for myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 101-106.	1.8	20
371	Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer. <i>Molecular Therapy</i> , 2012, 20, 2234-2243.	3.7	38
372	Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States. <i>Clinical Therapeutics</i> , 2012, 34, 1966-1976.	1.1	21
373	Implementing clinical trials on an international platform: Challenges and perspectives. <i>Journal of the Neurological Sciences</i> , 2012, 313, 1-6.	0.3	38
374	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.3	35
375	Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 864-873.	2.2	120
376	Psychometric evaluation of the myasthenia gravis composite using rasch analysis. <i>Muscle and Nerve</i> , 2012, 45, 820-825.	1.0	18
377	Recommendations for myasthenia gravis clinical trials. <i>Muscle and Nerve</i> , 2012, 45, 909-917.	1.0	122
378	Adopting an evidence-based lifestyle physical activity program: dissemination study design and methods. <i>Translational Behavioral Medicine</i> , 2012, 2, 199-208.	1.2	8

#	ARTICLE	IF	CITATIONS
379	Evolution of MS lesions to black holes under DNA vaccine treatment. <i>Journal of Neurology</i> , 2012, 259, 1375-1382.	1.8	15
380	Expanding occupational sun safety to an outdoor recreation industry: a translational study of the Go Sun Smart program. <i>Translational Behavioral Medicine</i> , 2012, 2, 10-18.	1.2	13
381	A Research Model for Investigating the Effects of Artificial Food Colorings on Children With ADHD. <i>Pediatrics</i> , 2011, 127, e1575-e1584.	1.0	15
382	Motivating Public School Districts to Adopt Sun Protection Policies. <i>American Journal of Preventive Medicine</i> , 2011, 41, 309-316.	1.6	19
383	Bayesian sample size determination under hypothesis tests. <i>Contemporary Clinical Trials</i> , 2011, 32, 393-398.	0.8	4
384	Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. <i>Bone</i> , 2011, 49, 356-367.	1.4	117
385	Estimating power with effect size versus slop differences: Both means and variance matter. , 2011, 7, 247-249.		5
386	Factors That Predict Adoption and Implementation of an Evidence-based Physical Activity Program. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 694.	0.2	0
387	Continued Benefits of a Technical Assistance Web Site to Local Tobacco Control Coalitions During a State Budget Shortfall. <i>Journal of Public Health Management and Practice</i> , 2011, 17, E10-E19.	0.7	2
388	Acute kidney injury and renal replacement therapy independently predict mortality in neonatal and pediatric noncardiac patients on extracorporeal membrane oxygenation. <i>Pediatric Critical Care Medicine</i> , 2011, 12, e1-e6.	0.2	147
389	Real-time quantitative polymerase chain reaction for enumeration of <i>Streptococcus mutans</i> from oral samples. <i>European Journal of Oral Sciences</i> , 2011, 119, 447-454.	0.7	32
390	Comparison of weight changes following unilateral and staged bilateral STN DBS for advanced PD. <i>Brain and Behavior</i> , 2011, 1, 12-18.	1.0	10
391	Practice parameters and focusing research: Plasma exchange for myasthenia gravis. <i>Muscle and Nerve</i> , 2011, 43, 625-626.	1.0	15
392	Got milk?. <i>Annals of Neurology</i> , 2011, 70, 3-4.	2.8	3
393	Physical Activity and Self-Reported Cardiovascular Comorbidities in Persons with Multiple Sclerosis: Evidence from a Cross-Sectional Analysis. <i>Neuroepidemiology</i> , 2011, 36, 183-191.	1.1	61
394	Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials. <i>Pediatrics</i> , 2011, 128, 729-739.	1.0	136
395	Risk of Serious Injury for Young Baseball Pitchers. <i>American Journal of Sports Medicine</i> , 2011, 39, 253-257.	1.9	357
396	Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1464-1471.	1.4	38

#	ARTICLE	IF	CITATIONS
397	Relative efficiency and sample size for cluster randomized trials with variable cluster sizes. <i>Clinical Trials</i> , 2011, 8, 27-36.	0.7	13
398	Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. <i>Multiple Sclerosis Journal</i> , 2011, 17, 725-733.	1.4	20
399	Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1122-1129.	1.4	102
400	Smokers with Multiple Sclerosis Are More Likely to Report Comorbid Autoimmune Diseases. <i>Neuroepidemiology</i> , 2011, 36, 85-90.	1.1	18
401	Supporting Tobacco Control. <i>Health Promotion Practice</i> , 2011, 12, 186S-194S.	0.9	2
402	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e16802.	1.1	14
403	Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. <i>BMC Cancer</i> , 2010, 10, 619.	1.1	67
404	Inhaled Nitric Oxide in preterm infants: a systematic review and individual patient data meta-analysis. <i>BMC Pediatrics</i> , 2010, 10, 15.	0.7	29
405	Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 749-760.	2.8	308
406	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 409-411.	2.8	40
407	Comparative analysis of therapeutic options used for myasthenia gravis. <i>Annals of Neurology</i> , 2010, 68, 797-805.	2.8	135
408	Composite MRI scores improve correlation with EDSS in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1117-1125.	1.4	35
409	Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity. <i>Multiple Sclerosis Journal</i> , 2010, 16, 926-934.	1.4	11
410	Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 829-839.	1.4	98
411	Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. <i>Multiple Sclerosis Journal</i> , 2010, 16, 840-847.	1.4	11
412	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	1.5	29
413	Sample Size in Obesity Trials: Patient Perspective Versus Current Practice. <i>Medical Decision Making</i> , 2010, 30, 68-75.	1.2	8
414	Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2010, 67, 1329-35.	4.9	65

#	ARTICLE	IF	CITATIONS
415	Environmental Cues to UV Radiation and Personal Sun Protection in Outdoor Winter Recreation. Archives of Dermatology, 2010, 146, 1241-7.	1.7	27
416	Temporal characteristics of cold pain perception. Neuroscience Letters, 2010, 480, 12-15.	1.0	4
417	Decreased accuracy in interpretation of community-based screening mammography for women with multiple clinical risk factors. Journal of Clinical Epidemiology, 2010, 63, 441-451.	2.4	17
418	Assessing changes in relapse rates in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1414-1421.	1.4	93
419	Requiring an amyloid β biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's and Dementia, 2010, 6, 367-377.	0.4	41
420	High frequency of adverse health behaviors in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 105-113.	1.4	135
421	Testing a Theory-Based Health Communication Program: A Replication of <i>Go Sun Smart</i> in Outdoor Winter Recreation. Journal of Health Communication, 2009, 14, 346-365.	1.2	15
422	Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year. Pediatrics, 2009, 124, 1333-1343.	1.0	32
423	Variability of Interpretive Accuracy Among Diagnostic Mammography Facilities. Journal of the National Cancer Institute, 2009, 101, 814-827.	3.0	22
424	Smoking Status over Two Years in Patients with Multiple Sclerosis. Neuroepidemiology, 2009, 32, 72-79.	1.1	21
425	Predictors of Radiologists' Perceived Risk of Malpractice Lawsuits in Breast Imaging. American Journal of Roentgenology, 2009, 192, 327-333.	1.0	38
426	A cross-sectional study of bone health in multiple sclerosis. Neurology, 2009, 73, 1394-1398.	1.5	69
427	Relapses in multiple sclerosis. Neurology, 2009, 73, 1612-1613.	1.5	3
428	Evidence of treatment benefit: is seeing believing or obfuscation by statistics?. Multiple Sclerosis Journal, 2009, 15, 1251-1252.	1.4	2
429	The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Multiple Sclerosis Journal, 2009, 15, 385-392.	1.4	191
430	Erratum to "The MCTX experience: Challenges in planning and executing an international, multicenter clinical trial" [J. Neuroimmunol. 2011;202(208):80-84]. Journal of Neuroimmunology, 2009, 217, 103.	1.1	1
431	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Annals of Neurology, 2009, 65, 268-275.	2.8	206
432	Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 2009, 256, 568-576.	1.8	238

#	ARTICLE	IF	CITATIONS
433	Influence of genetic background on tumor karyotypes: Evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. <i>Chromosome Research</i> , 2009, 17, 365-377.	1.0	74
434	MHC-dependent desensitization of intrinsic anti-self reactivity. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 171-185.	2.0	6
435	Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 820-833.	0.7	58
436	A Bayesian Method of Estimating Kappa Coefficient with Application to a Rheumatoid Arthritis Study. <i>Communications in Statistics - Theory and Methods</i> , 2009, 38, 3432-3444.	0.6	1
437	Retinal architecture predicts pupillary reflex metrics in MS. <i>Multiple Sclerosis Journal</i> , 2009, 15, 479-486.	1.4	20
438	Weight changes associated with unilateral STN DBS and advanced PD. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 709-711.	1.1	37
439	Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 674, 93-100.	0.9	56
440	Macular Volume Determined by Optical Coherence Tomography as a Measure of Neuronal Loss in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 1366-72.	4.9	165
441	Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis. <i>Muscle and Nerve</i> , 2008, 38, 957-963.	1.0	149
442	Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite. <i>Muscle and Nerve</i> , 2008, 38, 1553-1562.	1.0	105
443	Randomized Trial Evaluating Computer-Based Sun Safety Education for Children in Elementary School. <i>Journal of Cancer Education</i> , 2008, 23, 74-79.	0.6	12
444	<i>Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone</i>. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 344-347.	1.8	69
445	Rules of Evidence for Clinical Trials. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 233-237.	1.8	1
446	Testing the Long-Term Effects of the<i>Go Sun Smart</i> Worksite Health Communication Campaign: A Group-Randomized Experimental Study. <i>Journal of Communication</i> , 2008, 58, 447-471.	2.1	28
447	The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 80-84.	1.1	28
448	Increasing Sun Protection in Winter Outdoor Recreation. <i>American Journal of Preventive Medicine</i> , 2008, 34, 502-509.	1.6	36
449	Bayesian interim analysis in clinical trials. <i>Contemporary Clinical Trials</i> , 2008, 29, 751-755.	0.8	7
450	Optical coherence tomography: a window into the mechanisms of multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 664-675.	2.7	282

#	ARTICLE	IF	CITATIONS
451	Go Sun Smart. Communication Education, 2008, 57, 423-433.	0.7	8
452	Constraint-Induced Movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findings. Multiple Sclerosis Journal, 2008, 14, 992-994.	1.4	73
453	Effects of Program Exposure and Engagement With Tailored Prevention Communication on Sun Protection by Young Adolescents. Journal of Health Communication, 2008, 13, 619-636.	1.2	14
454	Randomized Trials on Consider This, a Tailored, Internet-Delivered Smoking Prevention Program for Adolescents. Health Education and Behavior, 2008, 35, 260-281.	1.3	66
455	Responsiveness and predictive values in PPMS. Neurology, 2008, 70, 1061-1062.	1.5	0
456	Mammography Facility Characteristics Associated With Interpretive Accuracy of Screening Mammography. Journal of the National Cancer Institute, 2008, 100, 876-887.	3.0	84
457	Retinal Imaging by Laser Polarimetry and Optical Coherence Tomography Evidence of Axonal Degeneration in Multiple Sclerosis. Archives of Neurology, 2008, 65, 924-8.	4.9	114
458	Comorbidity, socioeconomic status and multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1091-1098.	1.4	168
459	Reproducibility of Optical Coherence Tomography in Multiple Sclerosis. Archives of Neurology, 2008, 65, 1218-22.	4.9	72
460	Randomized Trial on the <i>5 a Day, the Rio Grande Way</i> Website, A Web-based Program to Improve Fruit and Vegetable Consumption in Rural Communities. Journal of Health Communication, 2008, 13, 230-249.	1.2	47
461	Novel designs for clinical trials in multiple sclerosis: another excursion to Sirenum scopuli?. Therapy: Open Access in Clinical Medicine, 2008, 5, 613-622.	0.2	1
462	Validation of NARCOMS Depression Scale. International Journal of MS Care, 2008, 10, 81-84.	0.4	18
463	Association, Cause, and Correlation. , 2008, , 279-294.		0
464	Validation of the NARCOMS registry: diagnosis. Multiple Sclerosis Journal, 2007, 13, 770-775.	1.4	111
465	Testing the risk compensation hypothesis for safety helmets in alpine skiing and snowboarding. Injury Prevention, 2007, 13, 173-177.	1.2	73
466	Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain, 2007, 127, 35-41.	2.0	227
467	Influence of Computer-Aided Detection on Performance of Screening Mammography. New England Journal of Medicine, 2007, 356, 1399-1409.	13.9	504
468	Interferon- β for multiple sclerosis: Long-term benefits?. Annals of Neurology, 2007, 61, 283-285.	2.8	7

#	ARTICLE	IF	CITATIONS
469	Randomized Trial on Sun Safety Education at Ski and Snowboard Schools in Western North America. <i>Pediatric Dermatology</i> , 2007, 24, 222-229.	0.5	28
470	Kinetics of Immune Tolerization in a Clinical Trial on Epitope-specific Therapy in Rheumatoid Arthritis (RA). <i>Clinical Immunology</i> , 2007, 123, S96-S97.	1.4	0
471	Effect of Emailed Messages on Return Use of a Nutrition Education Website and Subsequent Changes in Dietary Behavior. <i>Journal of Medical Internet Research</i> , 2007, 9, e27.	2.1	44
472	Nutrition Monitoring and Research Studies. , 2007, , 471-480.		0
473	Effects of the Sunny Days, Healthy Ways Curriculum on Students in Grades 6 to 8. <i>American Journal of Preventive Medicine</i> , 2006, 30, 13-22.	1.6	49
474	OR.2. Epitope-Specific Therapy in Rheumatoid Arthritis, Phase 2 Clinical and Immunological Results. <i>Clinical Immunology</i> , 2006, 119, S4.	1.4	1
475	Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis. <i>Ophthalmology</i> , 2006, 113, 324-332.	2.5	589
476	Mediation of a middle school skin cancer prevention program.. <i>Health Psychology</i> , 2006, 25, 616-625.	1.3	24
477	Infectious causes of multiple sclerosis. <i>Lancet Neurology</i> , The, 2006, 5, 887-894.	4.9	151
478	Reality Check: Perceived Versus Actual Performance of Community Mammographers. <i>American Journal of Roentgenology</i> , 2006, 187, 42-46.	1.0	37
479	Futility studies: Spending a little to save a lot. <i>Neurology</i> , 2006, 66, 626-627.	1.5	30
480	Early Inhaled Nitric Oxide Therapy in Premature Newborns with Respiratory Failure. <i>New England Journal of Medicine</i> , 2006, 355, 354-364.	13.9	343
481	Is Bayesian Analysis Ready for Use in Phase III Randomized Clinical Trials?. <i>Stroke</i> , 2005, 36, 1622-1623.	1.0	19
482	Assessing Accuracy of Mammography in the Presence of Verification Bias and Intrareader Correlation. <i>Biometrics</i> , 2005, 61, 259-268.	0.8	14
483	Randomized Trial Testing a Worksite Sun Protection Program in an Outdoor Recreation Industry. <i>Health Education and Behavior</i> , 2005, 32, 514-535.	1.3	76
484	Does Litigation Influence Medical Practice? The Influence of Community Radiologists' Medical Malpractice Perceptions and Experience on Screening Mammography. <i>Radiology</i> , 2005, 236, 37-46.	3.6	73
485	Community-Based Mammography Practice: Services, Charges, and Interpretation Methods. <i>American Journal of Roentgenology</i> , 2005, 184, 433-438.	1.0	23
486	Current Realities of Delivering Mammography Services in the Community: Do Challenges with Staffing and Scheduling Exist?. <i>Radiology</i> , 2005, 235, 391-395.	3.6	36

#	ARTICLE	IF	CITATIONS
487	Association between Mammography Timing and Measures of Screening Performance in the United States. <i>Radiology</i> , 2005, 234, 363-373.	3.6	91
488	Randomized Effectiveness Trial of a Computer-Assisted Intervention to Improve Diabetes Care. <i>Diabetes Care</i> , 2005, 28, 33-39.	4.3	105
489	Mammographers' Perception of Women's Breast Cancer Risk. <i>Medical Decision Making</i> , 2005, 25, 283-289.	1.2	19
490	Validation of the NARCOMS Registry: fatigue assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 583-584.	1.4	46
491	Validation of the NARCOMS Registry: pain assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 338-342.	1.4	39
492	Physician Predictors of Mammographic Accuracy. <i>Journal of the National Cancer Institute</i> , 2005, 97, 358-367.	3.0	132
493	Accuracy of Screening Mammography Interpretation by Characteristics of Radiologists. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1840-1850.	3.0	196
494	The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. <i>Multiple Sclerosis Journal</i> , 2004, 10, 55-60.	1.4	48
495	Radiologist Uncertainty and the Interpretation of Screening. <i>Medical Decision Making</i> , 2004, 24, 255-264.	1.2	27
496	Clinical characteristics of progressive relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 451-454.	1.4	26
497	Effect of Breast Augmentation on the Accuracy of Mammography and Cancer Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 442.	3.8	134
498	The MS Cooperative Research (MS-CORE) group: an alternate approach to fostering multicenter studies. <i>Multiple Sclerosis Journal</i> , 2004, 10, 332-335.	1.4	4
499	A practical randomized trial to improve diabetes care. <i>Journal of General Internal Medicine</i> , 2004, 19, 1167-1174.	1.3	79
500	CCR2-64I polymorphism and CCR5 ^{Δ32} deletion in patients with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2004, 225, 79-83.	0.3	35
501	The Association Between Obesity and Screening Mammography Accuracy. <i>Archives of Internal Medicine</i> , 2004, 164, 1140.	4.3	80
502	Enhancing antimelanoma immune responses through apoptosis. <i>Cancer Gene Therapy</i> , 2003, 10, 726-736.	2.2	43
503	Optimization of technique factors for a silicon diode array full-field digital mammography system and comparison to screen-film mammography with matched average glandular dose. <i>Medical Physics</i> , 2003, 30, 334-340.	1.6	37
504	Effect of relapses on development of residual deficit in multiple sclerosis. <i>Neurology</i> , 2003, 61, 1528-1532.	1.5	394

#	ARTICLE	IF	CITATIONS
505	A randomized controlled study of the acute and chronic effects of cooling therapy for MS. <i>Neurology</i> , 2003, 60, 1955-1960.	1.5	127
506	Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population. <i>Journal of Clinical Oncology</i> , 2003, 21, 4314-4321.	0.8	127
507	Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 289-292.	1.4	5
508	Factors that predict Health-Related Quality of Life in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 1-5.	1.4	61
509	Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography. <i>Annals of Internal Medicine</i> , 2003, 138, 168.	2.0	960
510	The Prevalence and Predictors of Helmet Use by Skiers and Snowboarders at Ski Areas in Western North America in 2001. <i>Journal of Trauma</i> , 2003, 55, 939-945.	2.3	24
511	Statistical issues in neutralizing antibodies. <i>Neurology</i> , 2003, 61, S38-9.	1.5	11
512	Performance comparison of full-field digital mammography to screen-film mammography in clinical practice. <i>Medical Physics</i> , 2002, 29, 830-834.	1.6	76
513	Clinical Comparison of Full-Field Digital Mammography and Screen-Film Mammography for Detection of Breast Cancer. <i>American Journal of Roentgenology</i> , 2002, 179, 671-677.	1.0	235
514	Detection of Ductal Carcinoma In Situ in Women Undergoing Screening Mammography. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1546-1554.	3.0	503
515	Performance of Diagnostic Mammography for Women With Signs or Symptoms of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1151-1159.	3.0	127
516	The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2002, 8, 359-365.	1.4	198
517	Mammography Screening and Differences in Stage of Disease by Race/Ethnicity. <i>American Journal of Public Health</i> , 2002, 92, 1144-1150.	1.5	78
518	The Effect of Degree of Refractive Error on Hydrogel Contact Lens-Induced Complications and Patient Self-Management Behaviors. <i>Optometry and Vision Science</i> , 2001, 78, 652-656.	0.6	10
519	Rates and Causes of Disagreement in Interpretation of Full-Field Digital Mammography and Film-Screen Mammography in a Diagnostic Setting. <i>American Journal of Roentgenology</i> , 2001, 176, 1241-1248.	1.0	67
520	Comparison of Full-Field Digital Mammography with Screen-Film Mammography for Cancer Detection: Results of 4,945 Paired Examinations. <i>Radiology</i> , 2001, 218, 873-880.	3.6	305
521	HYPOTHERMIA AS A RISK FACTOR FOR PEDIATRIC CARDIOTHORACIC SURGICAL SITE INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 459-462.	1.1	47
522	Nutrition Monitoring and Research Studies. , 2001, , .		0

#	ARTICLE	IF	CITATIONS
523	Clinical Significance of the Multiple Sclerosis Functional Composite. Archives of Neurology, 2000, 57, 1319-24.	4.9	116
524	Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). Multiple Sclerosis Journal, 2000, 6, 382-385.	1.4	44
525	New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 163-171.	1.4	147
526	Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet, The, 1999, 354, 1061-1065.	6.3	265
527	Promoting Cancer Screening among the First-Degree Relatives of Breast and Colorectal Cancer Patients: The Design of Two Randomized Trials. Preventive Medicine, 1999, 28, 229-242.	1.6	20
528	A Study of the Relationship Between Family History of Breast Cancer and Knowledge of Breast Cancer Genetic Testing Prerequisites. Cancer Detection and Prevention, 1999, 23, 22-30.	2.1	40
529	The Cancer Information Service Research Consortium: An Emerging Laboratory for Cancer Control Research. Preventive Medicine, 1998, 27, S3-S15.	1.6	31
530	The prospective relationships between smoking and weight in a young, biracial cohort: The Coronary Artery Risk Development in Young Adults study.. Journal of Consulting and Clinical Psychology, 1998, 66, 987-993.	1.6	92
531	Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. Journal of Pediatrics, 1997, 131, 55-62.	0.9	531
532	The Pediatric Costs of Strategies for Minimizing the Risk of Early-Onset Group B Streptococcal Disease. Obstetrics and Gynecology, 1997, 90, 347-352.	1.2	23
533	Long-Term Survival of African Americans in the Coronary Artery Surgery Study (CASS). Journal of the American College of Cardiology, 1997, 29, 358-364.	1.2	34
534	A Classification System to Evaluate Weight Maintainers, Gainers, and Losers. Journal of the American Dietetic Association, 1997, 97, 481-488.	1.3	45
535	Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Annals of Neurology, 1997, 42, 379-382.	2.8	342
536	Clinical outcomes assessment in multiple sclerosis: Part II. Multiple Sclerosis Journal, 1996, 2, 247-248.	1.4	0
537	Methodological issues in weight cycling. Annals of Behavioral Medicine, 1996, 18, 280-289.	1.7	15
538	Clinical outcomes assessment in multiple sclerosis. Annals of Neurology, 1996, 40, 469-479.	2.8	155
539	Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis. Annals of Neurology, 1995, 37, 5-6.	2.8	34
540	Psychological correlates of weight fluctuation. International Journal of Eating Disorders, 1995, 17, 263-275.	2.1	118

#	ARTICLE	IF	CITATIONS
541	Impact of patient history on residents' evaluation of child sexual abuse. <i>Child Abuse and Neglect</i> , 1995, 19, 943-951.	1.3	12
542	Fetal Growth in Women Using Low-Dose Aspirin for the Prevention of Preeclampsia: Effect of Maternal Size. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 1995, 4, 218-224.	0.7	16
543	The relationship between maternal and neonatal anthropometric measurements in term newborns. <i>Obstetrics and Gynecology</i> , 1995, 85, 192-196.	1.2	56
544	The Effect of Cigarette Smoking on Neonatal Anthropometric Measurements. <i>Obstetrics and Gynecology</i> , 1995, 85, 625-630.	1.2	155
545	Low-dose aspirin: Lack of association with an increase in abruptio placentae or perinatal mortality. <i>Obstetrics and Gynecology</i> , 1995, 85, 1055-1058.	1.2	32
546	A new device for collecting cord blood. <i>Obstetrics and Gynecology</i> , 1995, 86, 850-852.	1.2	2
547	Cervical examination and tocodynamometry at 28 weeks' gestation: Prediction of spontaneous preterm birth. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 666-671.	0.7	27
548	Who Are the Weight Maintainers?. <i>Obesity</i> , 1995, 3, 249s-259s.	4.0	19
549	Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 578-584.	0.7	37
550	Characteristics of Severe Hypoglycemia in the Patient With Insulin-Dependent Diabetes. <i>Southern Medical Journal</i> , 1994, 87, 616-620.	0.3	18
551	Strategies for the Prevention of Early-Onset Neonatal Group B Streptococcal Sepsis. <i>Obstetrics and Gynecology</i> , 1994, 83, 483-494.	1.2	204
552	Transmission of mutans streptococci to infants following short term application of an iodine-NaF solution to mothers' dentition. <i>Community Dentistry and Oral Epidemiology</i> , 1993, 21, 136-142.	0.9	38
553	Low-dose aspirin therapy to prevent preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 1083-1093.	0.7	176
554	Maternal risk factors and their influence on fetal anthropometric measurements. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 1197-1205.	0.7	47
555	Elevated levels of midtrimester maternal serum $\hat{\pm}$ -fetoprotein are associated with preterm delivery but not with fetal growth retardation. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 167, 596-601.	0.7	32
556	Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. <i>Urology</i> , 1992, 40, 36-40.	0.5	8
557	Effect of conventional dental restorative treatment on bacteria in saliva. <i>Community Dentistry and Oral Epidemiology</i> , 1992, 20, 138-143.	0.9	41
558	Distributed data analysis in a multicenter study: The CARDIA study. <i>Contemporary Clinical Trials</i> , 1992, 13, 80-90.	2.0	5

#	ARTICLE	IF	CITATIONS
559	Usefulness of various maternal skinfold measurements for predicting newborn birth weight. <i>Journal of the American Dietetic Association</i> , 1992, 92, 1393-1394.	1.3	10
560	Oral leukoplakia and adolescent smokeless tobacco use. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991, 72, 35-41.	0.6	24
561	The relationship between maternal serum zinc levels during pregnancy and birthweight. <i>Early Human Development</i> , 1991, 25, 75-85.	0.8	37
562	Cardiovascular risk factors in young adults. <i>Contemporary Clinical Trials</i> , 1991, 12, 1-77.	2.0	225
563	The Relationship Between Maternal Hematocrit and Pregnancy Outcome. <i>Obstetrics and Gynecology</i> , 1991, 77, 190-194.	1.2	109
564	Warning symptoms, uterine contractions, and cervical examination findings in women at risk of preterm delivery. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 748-754.	0.7	60
565	Alcohol intake and blood pressure in young adults: The CARDIA study. <i>Journal of Clinical Epidemiology</i> , 1990, 43, 1-13.	2.4	172
566	Cigarette smoking behavior is strongly related to educational status: The cardia study. <i>Preventive Medicine</i> , 1990, 19, 158-169.	1.6	157
567	Intrauterine growth retardation and preterm delivery: prenatal risk factors in an indigent population. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 213-218.	0.7	224
568	A Randomized, Controlled Trial of Very Early Prophylactic Ligation of the Ductus Arteriosus in Babies Who Weighed 1000 g or Less at Birth. <i>New England Journal of Medicine</i> , 1989, 320, 1511-1516.	13.9	237
569	Intrauterine growth retardation: Standards for diagnosis. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 161, 271-277.	0.7	142
570	Prematurity, postdates, and growth retardation: The influence of use of ultrasonography on reported gestational age. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 462-470.	0.7	94
571	Sensitivity, specificity and predictive value of saliva thiocyanate among pregnant women. <i>Addictive Behaviors</i> , 1989, 14, 447-452.	1.7	18
572	Preliminary Results from the Collaborative Alabama and Scandinavian Study of Successive Small-for-Gestational Age Births: Report from a Symposium in Trondheim 9th June 1988. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1989, 68, 19-25.	1.3	35
573	Cardia: study design, recruitment, and some characteristics of the examined subjects. <i>Journal of Clinical Epidemiology</i> , 1988, 41, 1105-1116.	2.4	1,409
574	Cost-Effectiveness of Prevention, Intervention, and Therapeutic Strategies in Coronary Artery Disease. <i>Drug Information Journal</i> , 1988, 22, 425-448.	0.5	0
575	Factors Associated with Discontinuation of Continuous Subcutaneous Insulin Infusion. <i>American Journal of the Medical Sciences</i> , 1988, 295, 23-28.	0.4	35
576	Comparison of Hypertension Prevalence and Control in 5,237 Rural and Urban Alabama Residents. <i>Southern Medical Journal</i> , 1987, 80, 1220-1223.	0.3	3

#	ARTICLE	IF	CITATIONS
577	Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) study. Contemporary Clinical Trials, 1987, 8, 68-73.	2.0	231
578	A study of the cost of tuberculosis contact investigation related to non-tuberculous Mycobacterial isolation in Jefferson County, Alabama. Public Health, 1987, 101, 297-304.	1.4	4
579	DDT contamination of a North Alabama aquatic ecosystem. Environmental Toxicology and Chemistry, 1986, 5, 725-736.	2.2	16
580	Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. Journal of the American College of Cardiology, 1985, 5, 1036-1045.	1.2	178
581	Neonatal mortality in infants born weighing 501 to 1000 grams. American Journal of Obstetrics and Gynecology, 1985, 151, 608-611.	0.7	15
582	Low birth weight, intrauterine growth retardation, and preterm delivery. American Journal of Obstetrics and Gynecology, 1985, 152, 980-984.	0.7	49
583	Issues in the natural history and treatment of coronary heart disease in black populations: Surgical treatment. American Heart Journal, 1984, 108, 688-694.	1.2	112
584	The Risk of Renal Calculi in Spinal Cord Injury Patients. Journal of Urology, 1984, 131, 857-859.	0.2	81
585	Response from Findley, et al. American Journal of Public Health, 1984, 74, 392-392.	1.5	0
586	Correlates of attendance and compliance in the hypertension detection and follow-up program. Contemporary Clinical Trials, 1982, 3, 13-27.	2.0	45
587	Three-year incidence of hypertension in thirteen U.S. communities. Preventive Medicine, 1982, 11, 487-499.	1.6	28
588	Development and validation of a VA risk function to predict mortality. Contemporary Clinical Trials, 1981, 2, 89.	2.0	0
589	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients With Parkinson's Disease and a <i>GBA</i> Mutation: Results From Part 1 of the Randomised, Double-Blinded, Placebo-Controlled MOVES-PD Trial. SSRN Electronic Journal, 0, , .	0.4	0
590	Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis. Journal of Neurology, 0, , .	1.8	4